BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 [Yahoo! Finance]
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
The BeiGene, Ltd. (NASDAQ:BGNE) First-Quarter Results Are Out And Analysts Have Published New Forecasts [Yahoo! Finance]
BeiGene, Ltd. (NASDAQ: BGNE) had its price target raised by analysts at TD Cowen from $236.00 to $254.00. They now have a "buy" rating on the stock.
BeiGene Reports First Quarter 2024 Financial Results and Business Updates